GLPwatch
Cagrilintide
Pipeline · Long-acting amylin analogue
Last updated 2026-05-28Cagrilintide is a long-acting drug designed to mimic amylin, a natural hormone in the body that helps control blood sugar and appetite. It is being developed as a potential treatment for obesity and related conditions, though it has not yet been approved for any specific use.
AI summary of the sources below.
| Mechanism | Long-acting amylin analogue A long-acting copy of amylin, a hormone that curbs appetite and slows stomach emptying. |
|---|---|
| Status | Pipeline |
| Branded products | — (none approved) |
| Manufacturer(s) | novo-nordisk |
How Cagrilintide connects
- Maker Novo Nordisk
- Trials 19 trials
- Research 24 papers
Trials (19)
- A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor
- Effects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease
- Investigating How CagriSema, Semaglutide and Cagrilintide Regulate Insulin Effects in the Body of People With Type 2 Diabetes
- A Research Study Looking Into How Cagrilintide Influences Food Intake and Appetite in People With Overweight or Obesity
- Research Study to Look at How Well Cagrilintide Together With Semaglutide Works in People With Type 2 Diabetes
- A Research Study to Compare Blood Levels of Cagrilintide and Semaglutide After Single Doses of Different Versions of Injectable CagriSema in Adults With Overweight or Obesity
- A Research Study to Compare Blood Levels of Two Different Versions of Cagrilintide in Adults With Excess Body Weight
- A Research Study Looking at How a Single Dose of the Medicine Cagrilintide Works in Participants With Reduced Liver Function and in Healthy Participants With Normal Liver Function and How Cagrilintide is Absorbed and Used by the Body
- A Research Study to Compare Blood Levels of Cagrilintide and Semaglutide After Combined Versus Separate Injections in People With Overweight or Obesity
- Weight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide
- A Research Study to Compare Blood Levels of Cagrilintide After Multiple Doses of Different Versions of Cagrilintide in Adults With Overweight or Obesity
- The Role of the Amylin Analogue Cagrilintide in Bone Metabolism
- Evaluation of the Tolerability of Cagrilintide in Participants Not Tolerating GLP-1-RA Therapies Due to Gastrointestinal Adverse Events
- A Study to See How Metabolism is Influenced by Weight Loss Due to Intervention With Cagrilintide and Semaglutide Compared to Diet
- A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and Placebo
- A Research Study Looking at How Cagrilintide Works on the Heart Rhythm in Healthy Participants
- Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide
- Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscle Health)
- A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
Top research (24)
- Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial.
- Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial.
- Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial.
- Development of Cagrilintide, a Long-Acting Amylin Analogue.
- Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity.
- Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes.
- Does receptor balance matter? - Comparing the efficacies of the dual amylin and calcitonin receptor agonists cagrilintide and KBP-336 on metabolic parameters in preclinical models.
- Cagrilintide plus semaglutide for obesity management.
- Cagrilintide: A Long-Acting Amylin Analog for the Treatment of Obesity.
- Efficacy and Safety of Cagrilintide Alone and in Combination with Semaglutide (Cagrisema) as Anti-Obesity Medications: A Systematic Review and Meta-Analysis.
- Structural and dynamic features of cagrilintide binding to calcitonin and amylin receptors.
- A Cross-Species Atlas of the Dorsal Vagal Complex Reveals Neural Mediators of Cagrilintide's Effects on Energy Balance.
- Cagrilintide lowers bodyweight through brain amylin receptors 1 and 3.
- Cagrilintide is not associated with clinically relevant QTc prolongation: A thorough QT study in healthy participants.
- Efficacy and Safety of Cagrilintide and Cagrisema Versus Semaglutide as Anti-Obesity Medications: A Systematic Review, Meta-Analysis and Meta-Regression.
- In adults with overweight or obesity, weekly subcutaneous cagrilintide-semaglutide increased weight loss at 68 wk.
- Cagrilintide-Semaglutide in Adults with Overweight or Obesity. Reply.
- Cagrilintide-Semaglutide in Adults with Overweight or Obesity.
- Cagrilintide-Semaglutide in Adults with Overweight or Obesity.
- Efficacy and safety of co-administered cagrilintide and semaglutide versus semaglutide alone in adults with overweight or obesity with or without type 2 diabetes in Japan and Taiwan (REDEFINE 5): a multicentre, randomised, active-controlled, phase 3a trial.
- Cagrilintide-Semaglutide in Adults with Overweight or Obesity.
- Cagrilintide-Semaglutide in Adults with Overweight or Obesity.
- Characterization of 0839 - A tool compound for pre-clinical mode-of-action studies of amylin analogues such as cagrilintide.
- Cagrilintide-Semaglutide in Adults with Overweight or Obesity. Reply.